| Literature DB >> 32122897 |
Charbel Al Khoury1,2, Nabil Nemer1, Georges Nemer3, Mazen Kurban3,4, Charlotte Bernigaud2,5, Katja Fischer6, Jacques Guillot7.
Abstract
Scabies is a frequent cutaneous infection caused by the mite Sarcoptes scabiei in a large number of mammals, including humans. As the resistance of S. scabiei against several chemical acaricides has been previously documented, the establishment of alternative and effective control molecules is required. In this study, the potential acaricidal activity of beauvericin was assessed against different life stages of S. scabiei var. suis and in comparison with dimpylate and ivermectin, two commercially available molecules used for the treatment of S. scabiei infection in animals and/or humans. The toxicity of beauvericin against cultured human fibroblast skin cells was evaluated using an MTT proliferation assay. In our in vitro model, developmental stages of S. scabiei were placed in petri dishes filled with Columbia agar supplemented with pig serum and different concentrations of the drugs. Cell sensitivity assays demonstrated low toxicity of beauvericin against primary human fibroblast skin cells. At 0.5 and 5 mM, beauvericin showed higher activity against adults and eggs of S. scabiei compared to dimpylate and ivermectin. These results revealed that the use of beauvericin is promising and might be considered for the treatment of S. scabiei infection.Entities:
Keywords: Sarcoptes scabieizzm321990; acaricide; beauvericin; in vitro test; mycotoxin; scabies
Mesh:
Substances:
Year: 2020 PMID: 32122897 PMCID: PMC7179650 DOI: 10.1128/AAC.02118-19
Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN: 0066-4804 Impact factor: 5.191